首页> 美国卫生研究院文献>other >MHC Multimer-Guided and Cell Culture-Independent Isolation of Functional T Cell Receptors from Single Cells Facilitates TCR Identification for Immunotherapy
【2h】

MHC Multimer-Guided and Cell Culture-Independent Isolation of Functional T Cell Receptors from Single Cells Facilitates TCR Identification for Immunotherapy

机译:MHC多聚体引导和单细胞功能性T细胞受体的细胞培养独立性促进了TCR识别的免疫治疗。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Adoptive therapy using T cells redirected to target tumor- or infection-associated antigens is a promising strategy that has curative potential and broad applicability. In order to accelerate the screening process for suitable antigen-specific T cell receptors (TCRs), we developed a new approach circumventing conventional in vitro expansion-based strategies. Direct isolation of paired full-length TCR sequences from non-expanded antigen-specific T cells was achieved by the establishment of a highly sensitive PCR-based T cell receptor single cell analysis method (TCR-SCAN). Using MHC multimer-labeled and single cell-sorted HCMV-specific T cells we demonstrate a high efficacy (approximately 25%) and target specificity of TCR-SCAN receptor identification. In combination with MHC-multimer based pre-enrichment steps, we were able to isolate TCRs specific for the oncogenes Her2eu and WT1 even from very small populations (original precursor frequencies of down to 0.00005% of CD3+ T cells) without any cell culture step involved. Genetic re-expression of isolated receptors demonstrates their functionality and target specificity. We believe that this new strategy of TCR identification may provide broad access to specific TCRs for therapeutically relevant T cell epitopes.
机译:使用重定向到靶标与肿瘤或感染相关的抗原的T细胞的过继治疗是一种有前途的策略,具有治愈潜力和广泛的适用性。为了加快筛选合适的抗原特异性T细胞受体(TCR)的过程,我们开发了一种新方法,可绕开基于常规体外扩增的策略。通过建立高度敏感的基于PCR的T细胞受体单细胞分析方法(TCR-SCAN),可以从未扩增的抗原特异性T细胞中直接分离成对的全长TCR序列。使用MHC多聚体标记的和单细胞分选的HCMV特异性T细胞,我们证明了TCR-SCAN受体鉴定的高功效(约25%)和靶标特异性。结合基于MHC-多聚体的预富集步骤,我们甚至能够从很小的人群中分离出特定于癌基因Her2 / neu和WT1的TCR(原始前体频率低至CD3 + T细胞),而无需任何细胞培养步骤。分离受体的基因重新表达证明了其功能和靶标特异性。我们相信,这种新的TCR识别策略可能为治疗相关T细胞表位提供对特定TCR的广泛访问。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号